Hinge Bio Secures $30 Million Series A’ Financing for Next-Generation Therapies via GEM-DIMER Platform

Funding:
Hinge Bio, a privately-held biotechnology company, has raised $30 million in Series A' financing led by Point72, with participation from Ridgeback Capital, InVivium Capital, and Lightswitch Capital, among others12.

Platform:
The funding will support the development of Hinge Bio's proprietary GEM-DIMER platform, which enables the creation of multivalent, multispecific antibody-based therapeutics for autoimmune, inflammatory, and infectious diseases, as well as cancer12.

Lead Candidate:
The company's lead product candidate, HB2198, is expected to enter clinical development in 2025 for the treatment of Systemic Lupus Erythematosus (Lupus) and other B cell-mediated autoimmune disorders12.

Therapeutic Goal:
HB2198 aims to achieve a reset of the immune system through rapid and deep B cell depletion in both peripheral blood and lymphoid tissues, offering convenience, accessibility, cost, and safety benefits of an off-the-shelf antibody-based therapeutic12.

Investor Confidence:
Investors believe that Hinge Bio's GEM-DIMER technology has broad applicability across therapeutic areas and constructs, with HB2198 showing promise as a best-in-disease therapeutic for multiple indications12.

Sources:

1. https://www.globenewswire.com/news-release/2025/01/15/3009892/0/en/Hinge-Bio-Raises-30-Million-Series-A-Financing-to-Develop-Next-Generation-Therapies-via-its-Proprietary-GEM-DIMER-Platform.html

2. https://www.biospace.com/press-releases/hinge-bio-raises-30-million-series-a-financing-to-develop-next-generation-therapies-via-its-proprietary-gem-dimer-platform